Decheng Capital
Overview
Decheng Capital is a global life sciences venture capital firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Everest Medicines | Jun 2020 | Series C | Co-investor |
| Cellares | Jun 2026 | Series D | Co-investor |
| GoodMood Holdings | Sep 2021 | Series C | Co-investor |
| Solve Therapeutics | Nov 2025 | VC Round | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Decheng Capital based?
Decheng Capital is headquartered in Menlo Park, California, United States.
When was Decheng Capital founded?
Decheng Capital was founded in 2012.
How many portfolio companies does Decheng Capital have?
Decheng Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Decheng Capital's portfolio?
Portfolio companies visible on Caplight include Everest Medicines, Cellares, GoodMood Holdings, Solve Therapeutics.
What was Decheng Capital's most recent investment shown here?
Decheng Capital's most recent investment in this portfolio sample was in Cellares in 2026.
What sectors does Decheng Capital focus on?
Decheng Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Frontier & Industrial Tech.
What company stages does Decheng Capital focus on?
Stage focus information for Decheng Capital is not publicly available.
What is Decheng Capital's AUM?
Decheng Capital's assets under management are estimated between $2.5B and $3.0B.